Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt No Debt
CLDX's Cash to Debt is ranked higher than
74% of the 1275 Companies
in the Global Biotechnology industry.

( Industry Median: 69.96 vs. CLDX: No Debt )
CLDX' s 10-Year Cash to Debt Range
Min: 2.73   Max: No Debt
Current: No Debt

Equity to Asset 0.88
CLDX's Equity to Asset is ranked higher than
87% of the 970 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. CLDX: 0.88 )
CLDX' s 10-Year Equity to Asset Range
Min: -0.32   Max: 0.94
Current: 0.88

-0.32
0.94
F-Score: 5
Z-Score: 33.04
M-Score: 2.56
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -4122.17
CLDX's Operating margin (%) is ranked higher than
54% of the 1050 Companies
in the Global Biotechnology industry.

( Industry Median: -71.67 vs. CLDX: -4122.17 )
CLDX' s 10-Year Operating margin (%) Range
Min: -2090.66   Max: -13.79
Current: -4122.17

-2090.66
-13.79
Net-margin (%) -3969.26
CLDX's Net-margin (%) is ranked higher than
54% of the 1050 Companies
in the Global Biotechnology industry.

( Industry Median: -75.86 vs. CLDX: -3969.26 )
CLDX' s 10-Year Net-margin (%) Range
Min: -2880.08   Max: -5.41
Current: -3969.26

-2880.08
-5.41
ROE (%) -42.54
CLDX's ROE (%) is ranked higher than
71% of the 1159 Companies
in the Global Biotechnology industry.

( Industry Median: -33.71 vs. CLDX: -42.54 )
CLDX' s 10-Year ROE (%) Range
Min: -2929.64   Max: -3.4
Current: -42.54

-2929.64
-3.4
ROA (%) -38.25
CLDX's ROA (%) is ranked higher than
69% of the 1279 Companies
in the Global Biotechnology industry.

( Industry Median: -27.24 vs. CLDX: -38.25 )
CLDX' s 10-Year ROA (%) Range
Min: -319.26   Max: -2.02
Current: -38.25

-319.26
-2.02
ROC (Joel Greenblatt) (%) -1117.79
CLDX's ROC (Joel Greenblatt) (%) is ranked higher than
68% of the 1249 Companies
in the Global Biotechnology industry.

( Industry Median: -347.70 vs. CLDX: -1117.79 )
CLDX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -4720   Max: -57.84
Current: -1117.79

-4720
-57.84
Revenue Growth (3Y)(%) -67.60
CLDX's Revenue Growth (3Y)(%) is ranked higher than
61% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: -0.50 vs. CLDX: -67.60 )
CLDX' s 10-Year Revenue Growth (3Y)(%) Range
Min: -67.6   Max: 105.3
Current: -67.6

-67.6
105.3
EPS Growth (3Y)(%) 133.60
CLDX's EPS Growth (3Y)(%) is ranked higher than
83% of the 708 Companies
in the Global Biotechnology industry.

( Industry Median: -8.20 vs. CLDX: 133.60 )
CLDX' s 10-Year EPS Growth (3Y)(%) Range
Min: -64.6   Max: 133.6
Current: 133.6

-64.6
133.6
» CLDX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

CLDX Guru Trades in Q1 2014

Columbia Wanger 2,672,000 sh (+59.9%)
Murray Stahl 26,335 sh (unchged)
Jean-Marie Eveillard Sold Out
Steven Cohen 1,818,631 sh (-48.14%)
» More
Q2 2014

CLDX Guru Trades in Q2 2014

Columbia Wanger 3,583,600 sh (+34.12%)
Murray Stahl 26,335 sh (unchged)
» More
Q3 2014

CLDX Guru Trades in Q3 2014

Jean-Marie Eveillard 250,000 sh (New)
Murray Stahl 26,335 sh (unchged)
Columbia Wanger 3,571,600 sh (-0.33%)
» More
Q4 2014

CLDX Guru Trades in Q4 2014

Jean-Marie Eveillard 559,542 sh (+123.82%)
Murray Stahl 26,335 sh (unchged)
Columbia Wanger 3,196,700 sh (-10.5%)
» More
» Details

Insider Trades

Latest Guru Trades with CLDX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Jean-Marie Eveillard 2014-12-31 Add 123.82%0.01%$12.55 - $20.93 $ 27.1363%559542
Jean-Marie Eveillard 2014-09-30 New Buy0.01%$12.05 - $17.57 $ 27.1387%250000
Jean-Marie Eveillard 2014-03-31 Sold Out 0.01%$16.95 - $31.59 $ 27.136%0
Andreas Halvorsen 2013-12-31 Sold Out 0.13%$21.51 - $36.71 $ 27.136%0
Jean-Marie Eveillard 2013-12-31 Reduce -75.45%0.04%$21.51 - $36.71 $ 27.136%135000
Andreas Halvorsen 2013-09-30 New Buy0.13%$18.37 - $36.01 $ 27.1319%672513
Jean-Marie Eveillard 2013-06-30 Reduce -45.89%0.02%$11.01 - $16.09 $ 27.13107%665560
George Soros 2012-06-30 Sold Out 0.06%$3.9 - $5.26 $ 27.13518%0
Jean-Marie Eveillard 2012-06-30 Add 260.87%0.02%$3.9 - $5.26 $ 27.13518%1660000
George Soros 2012-03-31 New Buy0.06%$2.77 - $5.46 $ 27.13578%803200
Jean-Marie Eveillard 2012-03-31 Add 360%0.01%$2.77 - $5.46 $ 27.13578%460000
Jean-Marie Eveillard 2011-12-31 Reduce -71.43%$2.11 - $3.21 $ 27.13905%100000
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 10.00
CLDX's P/B is ranked higher than
65% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 6.25 vs. CLDX: 10.00 )
CLDX' s 10-Year P/B Range
Min: 1.25   Max: 50.74
Current: 10

1.25
50.74
P/S 904.40
CLDX's P/S is ranked higher than
66% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 29.06 vs. CLDX: 904.40 )
CLDX' s 10-Year P/S Range
Min: 1.68   Max: 1268
Current: 904.4

1.68
1268
EV-to-EBIT -18.58
CLDX's EV-to-EBIT is ranked higher than
68% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. CLDX: -18.58 )
CLDX' s 10-Year EV-to-EBIT Range
Min: -36.6   Max: 0.3
Current: -18.58

-36.6
0.3
Current Ratio 10.63
CLDX's Current Ratio is ranked higher than
84% of the 1267 Companies
in the Global Biotechnology industry.

( Industry Median: 4.61 vs. CLDX: 10.63 )
CLDX' s 10-Year Current Ratio Range
Min: 0.56   Max: 16.03
Current: 10.63

0.56
16.03
Quick Ratio 10.63
CLDX's Quick Ratio is ranked higher than
85% of the 1267 Companies
in the Global Biotechnology industry.

( Industry Median: 4.41 vs. CLDX: 10.63 )
CLDX' s 10-Year Quick Ratio Range
Min: 0.56   Max: 16.03
Current: 10.63

0.56
16.03
Days Sales Outstanding 388.54
CLDX's Days Sales Outstanding is ranked higher than
88% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 114.29 vs. CLDX: 388.54 )
CLDX' s 10-Year Days Sales Outstanding Range
Min: 1.43   Max: 132.73
Current: 388.54

1.43
132.73

Valuation & Return

vs
industry
vs
history
Price/Net Cash 12.70
CLDX's Price/Net Cash is ranked higher than
80% of the 1357 Companies
in the Global Biotechnology industry.

( Industry Median: 56.66 vs. CLDX: 12.70 )
CLDX' s 10-Year Price/Net Cash Range
Min: 2.75   Max: 47.3
Current: 12.7

2.75
47.3
Price/Net Current Asset Value 12.50
CLDX's Price/Net Current Asset Value is ranked higher than
79% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 36.79 vs. CLDX: 12.50 )
CLDX' s 10-Year Price/Net Current Asset Value Range
Min: 2.73   Max: 45.93
Current: 12.5

2.73
45.93
Price/Tangible Book 11.60
CLDX's Price/Tangible Book is ranked higher than
69% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 9.29 vs. CLDX: 11.60 )
CLDX' s 10-Year Price/Tangible Book Range
Min: 2.18   Max: 55.86
Current: 11.6

2.18
55.86
Price/Median PS Value 37.70
CLDX's Price/Median PS Value is ranked higher than
67% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 2.46 vs. CLDX: 37.70 )
CLDX' s 10-Year Price/Median PS Value Range
Min: 0.07   Max: 49.34
Current: 37.7

0.07
49.34
Earnings Yield (Greenblatt) -5.00
CLDX's Earnings Yield (Greenblatt) is ranked higher than
73% of the 1255 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. CLDX: -5.00 )
CLDX' s 10-Year Earnings Yield (Greenblatt) Range
Min: -6.6   Max: 436.8
Current: -5

-6.6
436.8

Business Description

Industry: Biotechnology » Biotechnology
Compare:LH, ALR, DGX, LIFE, ENZ » details
Traded in other countries:TCE1.Germany,
Celldex Therapeutics, Inc., was incorporated in Delaware. The Company is a biopharmaceutical company focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases. Its drug candidate, rindopepimut (CDX-110), is an immunotherapeutic vaccine that targets the tumor-specific molecule, epidermal growth factor receptor variant III (EGFRvIII). EGFRvIII is a mutated form of the epidermal growth factor receptor (EGFR) that is only expressed in cancer cells and not in normal tissue and can directly contribute to cancer cell growth. Its other drug candidates include CDX-011 and CDX-1127. CDX-011 is an antibody-drug conjugate (ADC) that consists of a fully-human monoclonal antibody, CR011, linked to a potent cell-killing drug, monomethyl-auristatin E (MMAE). The CR011 antibody specifically targets glycoprotein NMB (GPNMB) that is expressed in a variety of human cancers including breast cancer. In December 2011, it completed enrollment of EMERGE, a randomized Phase 2b study of CDX-011 in patients with heavily pre-treated, advanced, GPNMB-positive breast cancer. It has additional clinical and preclinical programs, including CDX-1401, an APC Targeting Technology program, CDX-301, an immune cell mobilizing agent and dendritic cell growth factor and CDX-1135, a molecule that inhibits a part of the immune system called the complement system. The Company's products are derived from a broad set of complementary technologies which have the ability to utilize the human immune system and enable the creation of therapeutic agents. It is using these technologies to develop targeted immunotherapeutics comprised of antibodies, adjuvants and monotherapies and antibody-drug conjugates that prevent or treat cancer and other diseases that modify undesirable activity by the body's own proteins or cells. A number of its immunotherapeutic and antibody-drug conjugate drug candidates are in various stages of clinical trials. The Company faces competition from pharmaceutical and biotechnology companies both in the United States and abroad which include Arbor Pharmaceutics, Inc., AstraZeneca PLC, Bayer, Celgene Corporation, Eisai Inc., Eli Lilly and Company, Medigene AG, Northwest Biotherapeutics, Inc., Pfizer Inc., and Roche. In the United States, vaccines and immunotherapeutics for human use are subject to The Food and Drug Administration (FDA) approval as 'biologics' under the Public Health Service Act and 'drugs' under the Federal Food, Drug and Cosmetic Act.
» More Articles for CLDX

Headlines

Articles On GuruFocus.com
Cowen & Co Remains Bullish on Celldex Therapeutics Following FDA 'Breakthrough' Approval Feb 24 2015 
CLDX up 223%, Cohen Gains Big Apr 23 2013 
Steve Cohen Increases Celldex Up 145% Apr 06 2013 
comment on CLDX Mar 06 2013 
5 Resilient Biotech Stocks to Buy for 2012 Feb 28 2012 
CELLDEX THERAPEUTICS, INC (CLDX) CEO Anthony S Marucci buys 12,000 Shares Sep 13 2010 
Weekly CFO Buys Highlight: GNMK, RTIX, BKOR, PTEK, CLDX Sep 12 2010 
CELLDEX THERAPEUTICS, INC Reports Operating Results (10-Q) Aug 05 2010 
CELLDEX THERAPEUTICS, INC Reports Operating Results (10-Q) May 06 2010 
cooldecency99 note on CLDX May 01 2010 


More From Other Websites
Celldex Announces Exercise of Underwriters' Option to Purchase Additional Shares Feb 28 2015
Celldex Announces Exercise of Underwriters' Option to Purchase Additional Shares Feb 27 2015
Biotech Stock Mailbag: Receptos, Celldex Therapeutics, Exact Sciences Feb 27 2015
10-K for Celldex Therapeutics, Inc. Feb 26 2015
Celldex Therapeutics Prices Public Offering of Common Stock Feb 25 2015
Celldex Therapeutics Announces Proposed Public Offering of Common Stock Feb 25 2015
Celldex Therapeutics Prices Public Offering of Common Stock Feb 25 2015
6 stocks to watch Feb 25 2015
Celldex Therapeutics (CLDX) Stock Rises Today on Rintega FDA Designation, Fourth-Quarter Earnings Feb 24 2015
Celldex reports 4Q loss Feb 24 2015
Celldex reports 4Q loss Feb 24 2015
Celldex Therapeutics (CLDX) Wider-than-Expected Loss in Q4 - Tale of the Tape Feb 24 2015
CELLDEX THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Feb 24 2015
Celldex's Rindopepimut (Rintega(R)) Receives FDA Breakthrough Therapy Designation for the Treatment... Feb 24 2015
Celldex Reports Fourth Quarter and Year-End 2014 Results Feb 24 2015
Q4 2014 Celldex Therapeutics Inc Earnings Release - Before Market Open Feb 24 2015
Celldex Reports Fourth Quarter and Year-End 2014 Results Feb 24 2015
Will Celldex Therapeutics (CLDX) Disappoint This Earnings? - Analyst Blog Feb 23 2015
Celldex Therapeutics Shares Shooting Higher Feb 23 2015
Celldex's Rindopepimut (Rintega(R)) Receives FDA Breakthrough Therapy Designation for the Treatment... Feb 23 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK